Nuvectis Pharma Inc — Dividend History & Yield (NASDAQ:NVCT) | MetaTrader

Open full chart

Financials

Overview Estratto Conto Statistics Dividends

Quarterly Annual

Dividends per share 0000 — Dividend yield % 0000 — Payout ratio % 0000 —

Notizie

Nuvectis avvia trial di fase 1b combinando NXP900 con osimertinib

Nuvectis initiates phase 1b trial combining NXP900 with osimertinib

Nuvectis Pharma: H.C. Wainwright conferma rating Buy con target di $10

Nuvectis Pharma stock rating reiterated at Buy by H.C. Wainwright

Kaplan acquista azioni Nuvectis Pharma (NVCT) per un valore di $64.240

Il presidente di Nuvectis Pharma Bentsur acquista azioni per $28.600

Il direttore di Nuvectis Pharma Sanchez acquista azioni NVCT per 75.000$

H.C. Wainwright conferma il rating Buy su Nuvectis Pharma con target di $10

H.C. Wainwright reiterates Buy rating on Nuvectis Pharma stock at $10 target

Nuvectis Pharma adds former Intra-Cellular exec to board of directors

Nuvectis initiates phase 1b program for cancer drug NXP900

Nuvectis (NVCT) Q2 Loss Widens 43%